Skip to main content

Recursion Pharmaceuticals, Inc 8-K, filed Nov 2, 2026

Recursion Pharmaceuticals, Inc. (RXRX)

8-K 2026-11-02 For: 2026-10-31
View Original
Added on November 02, 2026

About this 8-K

Recursion Pharmaceuticals, Inc filed this 8-K on November 2, 2026, reporting on events of October 31, 2026.

Recursion presented Phase 2 REC-4881 data showing a 47% median polyp burden reduction in FAP patients after 12 weeks. Also, 85% of evaluable patients remained below baseline 12 weeks off treatment. AI summary

Items reported

  • Item 2.02: Financial results
  • Item 5.02: Director or officer change, or executive pay
  • Item 7.01: Regulation FD disclosure
  • Item 9.01: Financial statements and exhibits